ClinicalTrials.Veeva

Menu

Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (MECROV)

A

Asociación para Evitar la Ceguera en México

Status and phase

Terminated
Phase 4

Conditions

Macular Edema
Central Retinal Vein Occlusion

Treatments

Drug: bevacizumab and triamcinolone

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Full description

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Enrollment

10 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Macular edema secondary to central retinal vein occlusion
  • BCVA worse than 20/40
  • Central macular >250 mc with OCT

Exclusion criteria

  • Diabetic retinopathy or other retinopathy
  • Media opacity that does not allow following
  • steroid responder
  • diagnosed glaucoma or IOP > 21 mmHg

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

Carmen Conzalez-Mijares, Physician

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems